First-line metastatic RCC treatment outcomes in Europe
Research type
Research Study
Full title
Real-world first-line metastatic renal cell carcinoma (RCC) treatment outcomes in Europe
IRAS ID
321228
Contact name
Agne Jovaisaite
Contact email
Sponsor organisation
Queen Mary University
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
Immunotherapy, a form of therapy which uses the body’s immune system to fight cancer, is an effective treatment option for advanced kidney cancer. A recent clinical (CLEAR) trial has shown that a type of immunotherapy (pembrolizumab) and a commonly used anti-cancer agent (lenvatinib) can be used in combination to achieve improved survival outcomes in patients with advanced kidney cancer when compared to those treated with a standard anti-cancer agent (sunitinib). The European Society for Medical Oncology (ESMO) have subsequently published updated kidney cancer treatment guidelines in 2021, recommending the lenvatinib-pembrolizumab combination as a first-line treatment option for advanced kidney cancer in addition to the existing immunotherapy combinations. However, clinical trials are conducted in controlled settings with highly selective patient groups and therefore do not reflect the entire population of cancer patients receiving treatment. The survival outcomes in an unselected population are not well known. Our study will aim to produce a comprehensive database of first-line treatments received by patients with advanced kidney cancer in the United Kingdom, France, Germany and Spain, to assess first-line treatment patterns and their efficacy in the real-world to establish whether successful results seen in clinical trials are translated to improved outcomes in clinical practice.
REC name
South West - Central Bristol Research Ethics Committee
REC reference
23/SW/0048
Date of REC Opinion
13 Jun 2023
REC opinion
Further Information Favourable Opinion